Dr. Zamvil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2273Fax+1 415-353-2765
Education & Training
California Pacific Medical CenterInternship, Internal Medicine, 1988 - 1989
Stanford University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1989 - 2025
MA State Medical License 1990 - 2001- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis Start of enrollment: 2005 May 01
- Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- 3 citationsPredictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease.Akash Virupakshaiah, Vinicius A Schoeps, Jonathan Race, Michael Waltz, Siefaddeen Sharayah
Journal of Neurology, Neurosurgery, and Psychiatry. 2024-12-16 - 2 citationsProgramming tissue-sensing T cells that deliver therapies to the brain.Milos S Simic, Payal B Watchmaker, Sasha Gupta, Yuan Wang, Sharon A Sagan
Science. 2024-12-06 - HLA-transgenic mouse models to study autoimmune central nervous system diseases.Kyle R Pressley, Lance Schwegman, Maria Montes De Oca Arena, Carol Chase Huizar, Scott S Zamvil
Autoimmunity. 2024-12-01
Journal Articles
- Fibrin-Targeting Immunotherapy Protects Against Neuroinflammation and NeurodegenerationRaymond A Swanson, Scott S Zamvil, Lennart Mucke, Nature
- Functional Characterization of Reappearing B Cells After Anti-CD20 Treatment of CNS Autoimmune DiseaseScott Zamvil, MD, Proceedings of the National Academy of Sciences
Press Mentions
Killer T Cells Programmed for Tissue- and Tumor-Specific TargetingDecember 6th, 2024- Molecular Zip Code Draws Killer T Cells to Brain TumorsDecember 5th, 2024
- Potential Inverse DNA Vaccine for Multiple SclerosisAugust 15th, 2022
- Join now to see all
Grant Support
- B Cells In CNS AutoimmunityNational Institute Of Allergy And Infectious Diseases2009–2012
- Regulatory Monocytes In CNS Autoimmune DiseaseNational Institute Of Neurological Disorders And Stroke2009–2011
- Immunomodulation Of Inflammatory Disease By AtorvastatinNational Institute Of Allergy And Infectious Diseases2005–2009
- MHC Class II Regulation And Antigen Processing In EAENational Institute Of Neurological Disorders And Stroke2004–2008
- MHC Class II Transactivator (CIITA) In CNS AutoimmunityNational Institute Of Neurological Disorders And Stroke2001–2004
- B7 Costimulation And CNS Inflammatory DiseaseNational Institute Of Neurological Disorders And Stroke1998–1999
- B7 Costimulation And CNS Inflammatory DiseaseNational Institute Of Neurological Disorders And Stroke1994–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
